GNCA insider filings
GENOCEA BIOSCIENCES, INC. — 49 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-06-03. Screen GNCA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for GNCA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — GENOCEA BIOSCIENCES, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-06-03 | 4 | Duvall Diantha — CHIEF FINANCIAL OFFICER | Sale (S): 1,355 @ $0.06 | EDGAR |
| 2022-06-03 | 4 | Flechtner Jessica Baker — Chief Scientific Officer | Sale (S): 1,578 @ $0.06 | EDGAR |
| 2022-06-03 | 4 | Clark William D — President and CEO, Director | Sale (S): 4,023 @ $0.06 | EDGAR |
| 2022-06-02 | 4 | SUMER JACQUELYN L — CHIEF LEGAL & COMPLIANCE OFF | Sale (S): 2,500 @ $0.06 | EDGAR |
| 2022-06-02 | 4 | Clark William D — President and CEO, Director | Sale (S): 117,244 @ $0.06 | EDGAR |
| 2022-06-01 | 4 | Siber George — Director | Sale (S): 20,425 @ $0.07 | EDGAR |
| 2022-05-26 | 4 | STAPLETON RAYMOND D JR — CHIEF TECHNOLOGY OFFICER | Sale (S): 2,500 @ $0.09 | EDGAR |
| 2022-05-26 | 4 | Flechtner Jessica Baker — Chief Scientific Officer | Sale (S): 16,525 @ $0.09 | EDGAR |
| 2022-05-26 | 4 | Duvall Diantha — CHIEF FINANCIAL OFFICER | Sale (S): 24,407 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | Walker Paul Edward — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | Sonsini Peter W. — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | New Enterprise Associates 16, L.P. — 10% owner NEA Partners 16, L.P. — 10% owner NEA 16 GP, LLC — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | Makhzoumi Mohamad — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | Florence Anthony A. Jr. — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | Chang Carmen — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | Behbahani Ali — Director, 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | BASKETT FOREST — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-05-26 | 4 | SANDELL SCOTT D — 10% owner | Sale (S): 5,931,843 @ $0.07 · Sale (S): 4,445,093 @ $0.08 | EDGAR |
| 2022-04-05 | 4 | Flechtner Jessica Baker — Chief Scientific Officer | Sale (S): 1,212 @ $1.25 | EDGAR |
| 2022-04-05 | 4 | Duvall Diantha — CHIEF FINANCIAL OFFICER | Sale (S): 963 @ $1.25 | EDGAR |
| 2022-04-05 | 4 | Aakalu Girish N — CHIEF BUSINESS OFFICER | Sale (S): 963 @ $1.25 | EDGAR |
| 2022-04-05 | 4 | Clark William D — President and CEO, Director | Sale (S): 3,924 @ $1.25 | EDGAR |
| 2022-04-05 | 4 | Davis Thomas Andrew — CHIEF MEDICAL OFFICER | Sale (S): 1,091 @ $1.25 | EDGAR |
| 2022-03-17 | 4 | SUMER JACQUELYN L — CHIEF LEGAL & COMPLIANCE OFF | Grant/award (A): 37,500 @ $0 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | STAPLETON RAYMOND D JR — CHIEF TECHNOLOGY OFFICER | Grant/award (A): 43,750 @ $0 · Grant/award (A): 131,250 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Flechtner Jessica Baker — Chief Scientific Officer | Grant/award (A): 43,750 @ $0 · Sale (S): 3,349 @ $1.10 · Grant/award (A): 131,250 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Duvall Diantha — CHIEF FINANCIAL OFFICER | Grant/award (A): 37,500 @ $0 · Sale (S): 2,873 @ $1.10 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Aakalu Girish N — CHIEF BUSINESS OFFICER | Grant/award (A): 31,250 @ $0 · Sale (S): 2,397 @ $1.10 · Grant/award (A): 93,750 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Clark William D — President and CEO, Director | Grant/award (A): 150,000 @ $0 · Sale (S): 11,435 @ $1.10 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Davis Thomas Andrew — CHIEF MEDICAL OFFICER | Grant/award (A): 31,250 @ $0 · Sale (S): 2,717 @ $1.10 · Grant/award (A): 93,750 (derivative) @ $0 | EDGAR |
| 2022-03-07 | 4 | Lunger John — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-09-28 | 4 | Herron Jennifer Lyn — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Siber George — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Bosley Katrine — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Higgins Michael J — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Behbahani Ali — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Schwab Gisela — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | BATE KENNETH — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Duvall Diantha — CHIEF FINANCIAL OFFICER | Grant/award (A): 37,500 @ $0 · Grant/award (A): 112,500 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Flechtner Jessica Baker — Chief Scientific Officer | Grant/award (A): 43,750 @ $0 · Grant/award (A): 131,250 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Aakalu Girish N — CHIEF BUSINESS OFFICER | Grant/award (A): 31,250 @ $0 · Grant/award (A): 93,750 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | SUMER JACQUELYN L — CHIEF LEGAL & COMPLIANCE OFF | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | STAPLETON RAYMOND D JR — EVP PHARM SCI & MFG | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Clark William D — President and CEO, Director | Grant/award (A): 150,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 · Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Davis Thomas Andrew — CHIEF MEDICAL OFFICER | Grant/award (A): 31,250 @ $0 · Grant/award (A): 93,750 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-02 | 4 | SUMER JACQUELYN L — CHIEF LEGAL & COMPLIANCE OFF | Grant/award (A): 115,000 (derivative) @ $3.07 | EDGAR |
| 2021-02-18 | 4 | Clark William D — President and CEO, Director | Option exercise (M): 16,500 @ $1.66 · Option exercise (M): 19,998 @ $2.72 · Option exercise (M): 19,998 (derivative) @ $0 · Option exercise (M): 16,500 (derivative) @ $0 | EDGAR |
| 2021-02-01 | 4 | STAPLETON RAYMOND D JR — EVP PHARM SCI & MFG | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2020-11-10 | 4 | Clark William D — President and CEO, Director | Purchase (P): 4,760 @ $2.06 | EDGAR |
Recent 8-K events — GENOCEA BIOSCIENCES, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-06-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-24 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-28 | 8-K | ? 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-01-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-09-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-07-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GNCA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs